Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage

J. Ivanidze, R.A. Charalel, I. Shuryak, D. Brenner, A. Pandya, O.N. Kallas, K. Kesavabhotla, A.Z. Segal, M.S. Simon, and P.C. Sanelli

ABSTRACT

BACKGROUND AND PURPOSE: CT angiography and perfusion imaging is an important prognostic tool in the management of patients with aneurysmal subarachnoid hemorrhage. The purpose of this study was to perform a cost-effectiveness analysis of advanced imaging in patients with SAH, incorporating the risks of radiation exposure from CT angiography and CT perfusion imaging.

MATERIALS AND METHODS: The risks of radiation-induced brain cancer and cataracts were incorporated into our established decision model comparing the cost-effectiveness of CT angiography and CT perfusion imaging and transcranial Doppler sonography in SAH. Cancer risk was calculated by using National Cancer Institute methodology. The remaining input probabilities were based on literature data and a cohort at our institution. Outcomes were expected quality-adjusted life years gained, costs, and incremental cost-effectiveness ratios. One-way, 2-way, and probabilistic sensitivity analyses were performed.

RESULTS: CT angiography and CT perfusion imaging were the dominant strategies, resulting in both better health outcomes and lower costs, even when incorporating brain cancer and cataract risks. Our results remained robust in 2-way sensitivity analyses varying the prolonged latency period up to 30 years, with either brain cancer risk up to 50 times higher than the upper 95% CI limit or the probability of cataracts from 0 to 1. Results were consistent for scenarios that considered either symptomatic or asymptomatic patients with SAH. Probabilistic sensitivity analysis confirmed our findings over a broad range of selected input parameters.

CONCLUSIONS: While risks of radiation exposure represent an important consideration, CT angiography and CT perfusion imaging remained the preferred imaging compared with transcranial Doppler sonography in both asymptomatic and symptomatic patients with SAH, with improved health outcomes and lower health care costs, even when modeling a significantly higher risk and shorter latency period for both cataract and brain cancer than that currently known.

ABBREVIATIONS: CTAP = CT angiography and CT perfusion; NCI = National Cancer Institute; QALY = quality-adjusted life year; TCD = transcranial Doppler sonography

Aneurysmal subarachnoid hemorrhage is a devastating illness with the reported incidence estimated as 14.5 per 100,000 person years in the United States.¹ SAH is associated with a mortality of 15%, and approximately 58% of survivors experience functional disability, with global cognitive impairment being a major contributor to poor functional status.² SAH is also associ-

ated with a considerable economic burden, with average inpatient costs of \$150,101 for patients with symptomatic vasospasm in the United States and \$110,310 for patients without symptomatic vasospasm.³ A study conducted in the United Kingdom in 2010 found the total annual economic burden of SAH to be approximately £510 million (\$873.5 million),⁴ accounting for outpatient care, cerebrovascular rehabilitation, and social services. The same study found an estimated annual total of 74,807 quality-adjusted life years (QALYs) lost due to SAH. Therefore, SAH is associated with a substantial burden on health care resources, most of which are related to the long-term effects of functional and cognitive disability.

The marked increase in CT use during the past several decades

Received August 16, 2016; accepted after revision October 3.

From the Departments of Radiology (J.I., R.A.C., O.N.K., K.K., P.C.S.), Neurology (A.Z.S.), and Internal Medicine and Public Health (M.S.S.), Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York; Department of Radiology (I.S., D.B.), New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York; Department of Health Policy and Management (A.P.), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; and Department of Radiology (M.S.S., P.C.S.), Northwell Health, Manhasset, New York.

This work was supported by the Radiological Society of North America Research and Education Foundation (Resident Research Grant RRI429 to Jana Ivanidze).

Preliminary results of this work were presented as an oral scientific paper presentation at: Annual Meeting of the Radiological Society of North America, November 30 to December 5, 2014; Chicago, Illinois.

Please address correspondence to Jana Ivanidze, MD, PhD, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY 10065; e-mail: jai9018@nyp.org; @jana_ivanidze

<http://dx.doi.org/10.3174/ajnr.A5034>

Table 1: Input parameters added into the decision analytic model incorporating the effects of radiation exposure

Input Parameter	Value	Source
Probability of brain cancer	27.35 per 100,000 person years	Calculated using NCI methodology (Berrington de Gonzalez et al, ¹⁵ see main text for further details)
Probability of cataract	0.0025	Yuan et al ¹³
Latency of brain cancer	10.7 yr	Kranzinger et al ¹²
Latency of cataract	6 yr	Henk et al ¹⁴
Utility of brain cancer	0.69	de Rooij et al ¹⁹
Utility of cataract	0.86	Kallmes and Kallmes ²⁰
Cost of brain cancer	\$49,301.70	de Rooij et al ¹⁹
Cost of cataract	\$2692	Kallmes and Kallmes ²⁰

Table 2: Lifetime brain cancer risks^a

Age at Treatment (yr)	Sex	Life Expectancy (mRS Score)	Lifetime Brain Cancer Risk (per 100,000 Individuals) (Mean) (95% CI)
70	M	Normal (0–2)	8.14 (1.52–23.82)
70	M	Reduced (3–5)	2.33 (0.44–6.82)
70	F	Normal (0–2)	2.47 (0.52–6.84)
70	F	Reduced (3–5)	0.66 (0.14–1.83)
50	M	Normal (0–2)	27.35 (5.25–80.16) ^b
50	M	Reduced (3–5)	5.26 (1.01–15.40)
50	F	Normal (0–2)	7.32 (1.55–20.36)
50	F	Reduced (3–5)	1.39 (0.29–3.85)

^a Risks were calculated using NCI methodology (<https://irep.nci.nih.gov/radtrat/>), adjusted for life expectancy.¹⁵ The average dose for a CT+CTA+CTP examination was estimated from published literature.¹⁶

^b To assume a conservative approach, we used the highest modeled risk (50-year-old male patient with normal life expectancy) for our base case scenario.

has revolutionized the practice of medicine and is associated with a marked rise in administered radiation doses.⁵ This increase in radiation dose is attributable, in part, to the increased speed of image acquisition, allowing multiphase examinations to evaluate greater coverage of the body and provide functional information. This has resulted in a significant increase in the population's cumulative exposure to ionizing radiation and concern for the potential increase in cancer risk.⁶ In 2009, the US Food and Drug Administration issued a notification regarding the safety of CT perfusion in administering high radiation doses.⁷ Consequently, there has been a focus on reducing radiation exposure from medical imaging and evaluating the appropriate use of CT.⁸

The purpose of our study was to incorporate the short- and long-term risks of ionizing radiation exposure from CT angiography and CT perfusion (CTAP) imaging into our established cost-effectiveness decision model of patients with aneurysmal subarachnoid hemorrhage⁹ to determine whether the risks of radiation-induced brain cancer and cataracts would potentially alter the model results. In our previous work, which did not include the downstream effects of radiation exposure from CTAP on health outcomes and health care costs, our model results indicated that CTAP is the preferred imaging strategy compared with transcranial Doppler sonography (TCD), leading to improved clinical outcomes and lower health care costs in patients with SAH.⁹ Our hypothesis is that CTAP will remain the preferred imaging strategy in patients with SAH due to its relatively low risk from radiation exposure coupled with the high morbidity and mortality rates in this patient population.

MATERIALS AND METHODS

Model Structure

Our established decision-analysis model was developed by using the TreeAge Pro software program (Version 2013.1.0; TreeAge Software, Williamstown, Massachusetts).⁹ The model compares the health and economic consequences of 2 imaging strategies for management of SAH: TCD and CTAP. Following aneurysmal rupture, patients with SAH are classified as either symptomatic or asymptomatic for complications such as

vasospasm and/or delayed cerebral ischemia. The test result of either TCD or CTAP leads to management options, including no treatment (patient observation), immediate treatment with medical hypertensive therapy, and further testing by using digital subtraction angiography with potential interventional treatment. The organization of the branches in the model is based on the Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage published by the American Heart Association/American Stroke Association¹⁰ and a clinical decision-making algorithm derived from consultation with 4 neurologists specializing in neurointensive care at New York-Presbyterian Hospital Weill Cornell Campus for specific clinical scenarios.

Patient Population

The base case scenario is a 50-year-old patient, representing the average age in a previously described SAH cohort at our institution.⁹ Inclusion criteria for the empiric patient cohort are described in detail in our previously published decision analytic model.⁹ Briefly, this cohort included adult patients with documented aneurysmal SAH at admission enrolled in an internal review board–approved prospective diagnostic accuracy trial at our institution. Patients underwent aneurysm repair and were monitored in the neurologic intensive care unit, as per the standard of care. Patients were defined as symptomatic if they had documented clinical deterioration with the occurrence of focal neurologic impairment or a decrease of at least 2 points on the Glasgow Coma Scale that was new and not attributable to other causes. Patients who did not experience the above symptoms were defined as asymptomatic. All patients were imaged with CTAP on the day of occurrence of symptoms or on days 6–8 in case of asymptomatic patients. Patients who had negative CTAP findings were managed conservatively. Patients who had positive CTAP findings received medically induced hypertensive therapy as per standard guidelines.¹¹ Patients who did not respond to medical therapy proceeded to angiographic testing. If angiographic testing was positive for vasospasm, patients were treated intraprocedurally with intra-arterial verapamil.

Input Probabilities

Input Parameters Derived from Published Literature. Table 1 lists all input parameters incorporated in our expanded decision analytic model incorporating the effects of radiation exposure. All other preexisting input parameters are described in detail in our previously published decision analytic model.⁹ Probabilities were

Table 3: Cost-effectiveness analysis results: overall patient population^a

Strategy	Cost (\$)	Incremental Cost (\$)	Effectiveness (QALYs)	Incremental Effectiveness (QALYs)	Incremental Cost-Effectiveness Ratio (\$/QALY)
CTAP	147,116	—	13.81	—	—
TCD	154,718	7601	13.62	−0.1972	Dominated

^a CTAP imaging strategy is used as the reference in the incremental cost-effectiveness results.

FIG 1. Cost-effectiveness analysis results. The CTAP strategy had greater QALYs and lower cost than the TCD strategy after incorporating the risks of brain cancer and cataract.

FIG 2. Two-way sensitivity analysis on the probability of brain cancer and the latency of brain cancer overall in the patient population. The CTAP strategy is indicated in blue, and the TCD strategy is indicated in red. X denotes the base case (latency of brain cancer = 10.7 years based on published literature; modeled probability of brain cancer = 0.0002725; 95% CI, 0.000053–0.000802). A willingness-to-pay (WTP) threshold of \$100,000 was assumed.

calculated by using a conditionally dependent multinomial prediction model.

A mean brain cancer latency of 10.7 years after exposure was used in the model based on published literature.¹² The risk of cataract from radiation exposure related to CTAP was estimated

at 0.0025 based on published literature.¹³ The average latency of cataract is reported as 6 years after exposure.¹⁴

Risks from Radiation Exposure. Lifetime brain cancer risk from CTAP was calculated by using National Cancer Institute (NCI) methodology (<https://irep.nci.nih.gov/radtrat/>) and adjusted for life expectancy.¹⁵ As demonstrated in Table 2, the risks differed on the basis of patient sex, age, and life expectancy. We conservatively elected to use the highest modeled risk as the base case risk of radiation-induced brain cancer included in the model, which was 27.25 per 100,000 persons per year (95% CI, 5.3–80.2 per 100,000) in a 50-year-old male patient with normal life expectancy (Table 2). The average brain effective dose from NCCT/CTAP used in the risk calculation was 16.4 mSv (range, 11.8–27.3 mSv), and the mean dose-length product was 6790.0 mGy × cm, based on published literature.¹⁶ Of note, this mean effective dose has been further decreased in recent years, with published studies citing comprehensive acute stroke protocol NCCT/CTAP doses of up to 10.6 mSv.¹⁷ However, we sought a conservative approach and elected to use the

higher mean effective dose of 16.4 mSv because the empiric patient cohort used as a basis for our decision analytic model had received this dose. Furthermore, our model results would represent the higher limit of radiation exposure from CTAP imaging in this cohort.

Outcomes

Health Outcomes. Outcome health states reflect functional outcomes from SAH, incorporating quality-of-life impairments associated with cataract formation and developing brain cancer.

The probabilities for long-term clinical outcomes from SAH, representing health states, were categorized as recovered (mRS, 0–2), disability (mRS, 3–5), or death (mRS, 6) and were derived from the International Subarachnoid Aneurysm Trial.¹

Utility Weights and Quality-Adjusted Life Years. Utilities were calculated as a weighted average from a systematic review of utilities assigned according to mRS scores. The utilities of recovered and disability were 0.80 and 0.22, respectively.¹⁸ Life expectancies in each health state were derived from literature review as 28 years for recovered (mRS, 0–2),¹⁹ and 10.8 years for disability (mRS, 3–5).²⁰ Death was assigned a value of zero for both life years and utility.

The utility of brain cancer of 0.692 was assumed on the basis of published literature.²¹ The utility of cataract of 0.86 was assumed on the basis of published literature.²²

Table 4: One-way sensitivity analysis results: probability of cataract^a

Probability of Cataract	Strategy	Cost (\$)	Effectiveness (QALYs)	Incremental Cost (\$)	Incremental Effectiveness (QALYs)	Incremental Cost-Effectiveness Ratio (\$/QALY)
0	CTAP	147,110	13.81	0	0	
0	TCD	154,719	13.62	7608.40	-0.20	Dominated
0.2	CTAP	147,625	13.80	0	0	
0.2	TCD	154,719	13.62	7094.12	-0.18	Dominated
0.4	CTAP	148,139	13.78	0	0	
0.4	TCD	154,719	13.62	6579.84	-0.17	Dominated
0.6	CTAP	148,653	13.77	0	0	
0.6	TCD	154,719	13.62	6065.56	-0.15	Dominated
0.8	CTAP	149,168	13.75	0	0	
0.8	TCD	154,719	13.62	5551.28	-0.13	Dominated
1	CTAP	149,682	13.73	0	0	
1	TCD	154,719	13.62	5037.00	-0.12	Dominated

^a In a 1-way sensitivity analysis, CTAP remained the optimal strategy when varying the probability of cataract from 0.0 to 1.0.

FIG 3. Two-way sensitivity analysis on the probability of brain cancer and the latency of brain cancer and subanalysis of the asymptomatic patient population. The CTAP strategy is indicated in blue, and the TCD strategy is indicated in red. X denotes the base case (latency of brain cancer = 10.7 years based on published literature; modeled probability of brain cancer = 0.0002725; 95% CI, 0.000053–0.000802). A willingness-to-pay (WTP) threshold of \$100,000 was assumed.

Health outcomes were expressed as quality-adjusted-life years gained for each imaging strategy. Lifetime QALYs were calculated by multiplying the sum of the number of years spent in each health state by the utility associated with that state.

Cost Outcomes. Evaluation of costs included only direct medical costs; indirect costs such as loss of earnings through inability to work were omitted according to standard methods in performing cost-effectiveness analyses in the United States. Imaging costs were based on the 2012 Medicare rates (including both technical and professional fees) based on the Current Procedural Terminology codes. The 2012 rates were chosen to maintain consistency with our empiric cohort. The total costs for long-term care in each health state were estimated from the literature and multiplied by the life expectancy. Current values for both benefits and costs were calculated by discounting the original values at a rate of 3% per year, as recommended for cost-effectiveness analyses in the United States.²³ Costs of brain cancer²⁴ and cataract surgery²⁵ were estimated on the basis of published literature.

Statistical Analyses

Incremental cost-effectiveness ratios were calculated as well as the incremental cost per QALY gained. Univariable and multivariable sensitivity analyses were performed to determine the independent and combined effect of input parameter uncertainty. A willingness-to-pay threshold of \$100,000/QALY was assumed on the basis of previously published work.⁹ Two-way sensitivity analyses were performed to evaluate the impact of the following: 1) the probability of brain cancer and latency until brain cancer development, and 2) the probability of cataract and latency until cataract development based on model results. A scenario analysis considering only asymptomatic patients was also performed.

To assess overall model uncertainty, we conducted probabilistic sensitivity analysis in which 10,000 simulations were performed. The selected key variables were assumed to have triangular distributions. In a separate probabilistic sensitivity analysis, the range of the probability of brain cancer was extended to incorporate an upper limit of 5% (>50 times the upper limit of the 95% confidence interval), and 10,000 simulations of the model were repeated.

RESULTS

The per-person cost for the CTAP strategy was \$147,116. The per-person cost for the TCD strategy was \$154,718. The CTAP strategy resulted in a gain of 13.81 QALYs. The TCD strategy resulted in a gain of 13.62 QALYs (Table 3). Because the CTAP strategy resulted in lower cost and greater gains in QALYs, the CTAP strategy was dominant over the TCD strategy. When we varied the probability of brain cancer, the CTAP strategy remained cost-effective at \$100,000/QALY as long as the risk of brain cancer remained lower than approximately 4%, compared with 0.03% in the base case. This threshold value was 50 times greater than the upper limit of the 95% confidence interval (0.08%) (Figs 1 and 2). Our results remained robust when varying the latency of brain cancer onset from 0.1 years to 30 years at base case brain cancer risk (Fig 2).

In 2-way sensitivity analysis, the CTAP strategy remained dominant over the TCD strategy under all circumstances when the probability of cataract was varied from 0 to 1 and cataract

Table 5: Cost-effectiveness analysis results: asymptomatic patient population subanalysis^a

Strategy	Cost (\$)	Incremental Cost (\$)	Effectiveness (QALYs)	Incremental Effectiveness (QALYs)	Incremental Cost-Effectiveness Ratio (\$/QALY)
CTAP	145,247	—	13.86	—	—
TCD	156,272	11,024	13.51	−0.3517	Dominated

^a CTAP imaging strategy is used as the reference in the incremental cost-effectiveness results.

FIG 4. Cost-effectiveness (CE) acceptability curves. CE acceptability curves were calculated incorporating distributions reported in the literature and the probability of brain cancer as modeled on the basis of NCI methodology (A, see Table 1) and, in a separate subanalysis, incorporating an upper limit of the probability of brain cancer of 5% (ie, >50 times higher than the calculated 95% confidence interval upper limit of 80.16 per 100,000, B).

latency was varied from 0.1 to 30 years. Table 4 demonstrates results of a 1-way sensitivity analysis varying the probability of cataract from 0 to 1 when there was no condition for which TCD was preferred.

A scenario analysis of asymptomatic patients with SAH did not change the results; CTAP remained the dominant strategy compared with TCD (Fig 3 and Table 5).

In probabilistic sensitivity analysis, CTAP was the preferred strategy in 100% of iterations across a broad range of willingness-to-pay threshold values (Fig 4A). When the upper limit of the probability distribution for developing brain cancer was increased to 5% (compared with the upper limit of the 95% confidence interval, 0.08%; Table 2), CTAP was still preferred in >92% of iterations at a willingness-to-pay value below \$100,000/QALY (Fig 4B).

DISCUSSION

Our model demonstrates that while the development of brain cancer and cataract from radiation exposure in patients undergoing CTAP is an important consideration, it does not alter CTAP as the preferred imaging strategy in SAH compared with TCD. Similar to our prior analysis that did not incorporate these radiation-induced complications, we found that CTAP leads to greater quality-adjusted life expectancy for patients with SAH and lower health care costs after incorporating brain cancer and cataract risk. These findings were robust across a broad range of plausible values and remained consistent even after modeling a significantly higher risk and shorter latency period than known from current literature. Moreover, we conservatively elected to use the highest modeled risk (50-year-old male patient with normal life expectancy) for our base case scenario. This age approximates the median age of a patient with SAH in published cohorts.¹ If we had assumed a higher age or additional comorbidities, results would have been even more favorable for CTAP because of lower lifetime brain cancer risk (Table 2).

In recent years, CTAP has become increasingly recognized as an important prognostic tool in patients with SAH, especially given the recognized importance of cerebral blood flow evaluation

in the prediction of poor clinical outcomes.²⁶ Moreover, recent studies have shown that blood-brain barrier permeability evaluation with CTAP may become an important early prognostic marker of global cerebral edema²⁷ and delayed cerebral isch-

emia.²⁸ Early identification of these complications before they become apparent on noncontrast CT further increases the utility of CTAP. Furthermore, CTAP radiation doses have gradually decreased in recent years in an effort to decrease radiation exposure to the patient, with published studies citing comprehensive acute stroke protocol NCCT/CTAP doses of up to 10.6 mSv.¹⁷ Therefore, the radiation risk assumed in our model may, in fact, be overestimated, further supporting CTAP as the superior imaging technique in patients with SAH.

While radiation risk is an important consideration when selecting the appropriate imaging technique, our study shows that after we account for the risk of developing radiation-induced brain cancer and the risk of developing radiation-induced cataract, CTAP remains the superior imaging technique in patients with SAH, resulting in improved clinical outcomes and lower health care costs. This has important implications in the clinical decision-making for the management of patients with SAH, supporting the use of CTAP imaging.

The main limitation of our study is that a decision-modeling study design was performed instead of a prospective randomized clinical trial. Decision analytic models can help inform clinical decision-making by considering all potential consequences, incorporating the best available evidence, and considering uncertainty in estimates. Such models are particularly useful when randomized controlled trials are not feasible, such as in the case of gauging the contribution of radiation exposure effects on management strategies for SAH. This scenario is particularly relevant in this study given the long-term latency period associated with radiation-induced brain cancer. Another limitation in decision modeling is the variability of the input parameters. However, we performed several types of sensitivity analyses (1-way, 2-way, and probabilistic) to assess the variability of each input in the model results.

CONCLUSIONS

While there have been, to our knowledge, no randomized trials directly comparing the impact of different imaging modalities on clinical outcomes of patients with SAH, recent publications have demonstrated the added benefit of CTAP imaging in the detection of vasospasm and perfusion deficits.^{9,29} Moreover, CT perfusion imaging has the added benefit of evaluating delayed cerebral ischemia, an important SAH complication and determinant of poor clinical outcomes in SAH,²⁶ which is particularly important given the limitations of clinical examination³⁰ and TCD³¹ in this patient population.

Until recently, the focus has been on avoiding any kind of radiation exposure related to CT-based imaging, focusing on sonography-based methods instead. However, our study shows that the significant health benefits of CTAP outweigh the risks related to radiation exposure, even when modeling a far greater brain cancer risk than has been determined by using NCI methodology.

Future studies assessing the clinical and cost effectiveness of other imaging studies associated with radiation exposure should include the short- and long-term effects of radiation exposure to provide a comprehensive analysis of the benefits and risks for a given patient population.

Disclosures: Jana Ivanidze—RELATED: Grant: Radiological Society of North America Research and Education Foundation Resident Research Grant; Comments: Resident Research Grant (awarded to J.I.) 2014–2015.

REFERENCES

1. Molyneux AJ, Kerr RS, Birks J, et al; ISAT Collaborators. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. *Lancet Neurol* 2009;8:427–33 CrossRef Medline
2. Springer MV, Schmidt JM, Wartenberg KE, et al. Predictors of global cognitive impairment 1 year after subarachnoid hemorrhage. *Neurosurgery* 2009;65:1043–50; discussion 1050–51 CrossRef Medline
3. Chou CH, Reed SD, Allsbrook JS, et al. Costs of vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2010;67:345–51; discussion 351–52 CrossRef Medline
4. Rivero-Arias O, Gray A, Wolstenholme J. Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. *Cost Eff Resour Alloc* 2010;8:6 CrossRef Medline
5. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. *Arch Intern Med* 2009;169:2078–86 CrossRef Medline
6. Amis ES Jr, Butler PF; American College of Radiology. ACR white paper on radiation dose in medicine: three years later. *J Am Coll Radiol* 2010;7:865–70 CrossRef Medline
7. Wintermark M, Lev MH. FDA investigates the safety of brain perfusion CT. *AJNR Am J Neuroradiol* 2010;31:2–3 CrossRef Medline
8. Goehler A, Gazelle GS. Examining the use of comparative and cost-effectiveness analyses in radiology. *AJR Am J Roentgenol* 2014;203:939–44 CrossRef Medline
9. Sanelli PC, Pandya A, Segal AZ, et al. Cost-effectiveness of CT angiography and perfusion imaging for delayed cerebral ischemia and vasospasm in aneurysmal subarachnoid hemorrhage. *AJNR Am J Neuroradiol* 2014;35:1714–20 CrossRef Medline
10. Meyers PM, Schumacher HC, Higashida RT, et al; Joint Writing Group of the Technology Assessment Committee, Society of NeuroInterventional Surgery, Society of Interventional Radiology, Joint Section on Cerebrovascular Neurosurgery of the American Association of Neurological Surgeons and Congress of Neurological Surgeons, Section of Stroke and Interventional Neurology of the American Academy of Neurology. Reporting standards for endovascular repair of saccular intracranial cerebral aneurysms. *J Neurointerv Surg* 2010;2:312–23 CrossRef Medline
11. Miller JA, Dacey RG Jr, Diringner MN. Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. *Stroke* 1995;26:2260–66 CrossRef Medline
12. Kranzinger M, Jones N, Rittinger O, et al. Malignant glioma as a secondary malignant neoplasm after radiation therapy for craniopharyngioma: report of a case and review of reported cases. *Onkologie* 2001;24:66–72 Medline
13. Yuan MK, Tsai DC, Chang SC, et al. The risk of cataract associated with repeated head and neck CT studies: a nationwide population-based study. *AJR Am J Roentgenol* 2013;201:626–30 CrossRef Medline
14. Henk JM, Whitelocke RA, Warrington AP, et al. Radiation dose to the lens and cataract formation. *Int J Radiat Oncol Biol Phys* 1993;25:815–20 CrossRef Medline
15. Berrington de Gonzalez A, Iulian Apostoaie A, Veiga LH, et al. RadRAT: a radiation risk assessment tool for lifetime cancer risk projection. *J Radiol Prot* 2012;32:205–22 CrossRef Medline
16. Mnyusiwalla A, Aviv RI, Symons SP. Radiation dose from multidetector row CT imaging for acute stroke. *Neuroradiology* 2009;51:635–40 CrossRef Medline
17. Diekmann S, Siebert E, Juran R, et al. Dose exposure of patients undergoing comprehensive stroke imaging by multidetector-row CT: comparison of 320-detector row and 64-detector row CT scanners. *AJNR Am J Neuroradiol* 2010;31:1003–09 CrossRef Medline
18. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. *Stroke* 2001;32:1425–29 CrossRef Medline
19. de Rooij NK, Linn FH, van der Plas JA, et al. Incidence of subarach-

- noid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry* 2007;78:1365–72 [CrossRef Medline](#)
20. Kallmes DF, Kallmes MH. **Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms.** *AJNR Am J Neuroradiol* 1997;18:1453–62 [Medline](#)
 21. McCarter H, Furlong W, Whitton AC, et al. **Health status measurements at diagnosis as predictors of survival among adults with brain tumors.** *J Clin Oncol* 2006;24:3636–43 [CrossRef Medline](#)
 22. Busbee BG, Brown MM, Brown GC, et al. **Cost-utility analysis of cataract surgery in the second eye.** *Ophthalmology* 2003;110:2310–17 [CrossRef Medline](#)
 23. Weinstein MC, Siegel JE, Gold MR, et al. **Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.** *JAMA* 1996;276:1253–58 [CrossRef Medline](#)
 24. Martino J, Gomez E, Bilbao JL, et al. **Cost-utility of maximal safe resection of WHO grade II gliomas within eloquent areas.** *Acta Neurochir (Wien)* 2013;155:41–50 [CrossRef Medline](#)
 25. Camejo MD, Rupani MK, Rebenitsch RL. **A comparative analysis of the cost of cataract surgery abroad and in the United States.** *Indian J Ophthalmol* 2014;62:748–49 [CrossRef Medline](#)
 26. Sanelli PC, Anumula N, Johnson CE, et al. **Evaluating CT perfusion using outcome measures of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.** *AJNR Am J Neuroradiol* 2013;34:292–98 [CrossRef Medline](#)
 27. Ivanidze J, Kallas ON, Gupta A, et al. **Application of blood-brain barrier permeability imaging in global cerebral edema.** *AJNR Am J Neuroradiol* 2016;37:1599–603 [CrossRef Medline](#)
 28. Ivanidze J, Kesavabhotla K, Kallas ON, et al. **Evaluating blood-brain barrier permeability in delayed cerebral infarction after aneurysmal subarachnoid hemorrhage.** *AJNR Am J Neuroradiol* 2015;36:850–54 [CrossRef Medline](#)
 29. Dankbaar JW, de Rooij NK, Velthuis BK, et al. **Diagnosing delayed cerebral ischemia with different CT modalities in patients with subarachnoid hemorrhage with clinical deterioration.** *Stroke* 2009;40:3493–98 [CrossRef Medline](#)
 30. Schmidt JM, Wartenberg KE, Fernandez A, et al. **Frequency and clinical impact of asymptomatic cerebral infarction due to vasospasm after subarachnoid hemorrhage.** *J Neurosurg* 2008;109:1052–59 [CrossRef Medline](#)
 31. Carrera E, Schmidt JM, Oddo M, et al. **Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage.** *Neurosurgery* 2009;65:316–23; discussion 323–24 [CrossRef Medline](#)